<p><strong>新加坡，2025 年 12 月 30 日（GLOBE NEWSWIRE）--</strong> EUDA Health Holdings Limited（纳斯达克：EUDA）“EUDA” 或 “公司”，是一家总部位于新加坡的非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国，今天宣布在中国推出其全国性的干细胞提取、低温存储和临床交付平台。公司已与深圳英诺免疫有限公司和武汉凯恩医院建立合作关系，继续扩展其全国临床和物流网络。该平台标志着 EUDA 在干细胞战略持续推进中的重要一步，进一步扩展了其在细胞提取、处理、低温存储、物流和临床应用方面的能力。</p>
<p><strong>核心平台设计原则</strong></p>
<p>EUDA 的平台围绕三个核心原则设计：集中处理与分散访问相结合，以确保质量和合规性而不限制地理覆盖范围；长期细胞保存，使患者能够在生命早期存储生物材料以备未来临床使用；与长寿医学的整合，使细胞服务嵌入更广泛的预防、再生和个性化健康计划中。</p>
<p><strong>国家干细胞提取和低温存储基础设施</strong></p>
<p>EUDA 的平台被设计为一个闭环、合规的操作系统，使患者能够在广泛的地理范围内访问干细胞服务，同时保持集中处理标准。</p>
<p>关键要素包括：</p>
<p>• 深圳英诺免疫有限公司作为 EUDA 在中国南方的主要细胞处理和低温存储中心，初步设计的低温存储能力约为 50,000 个患者细胞单位，处于受控条件下。</p>
<p>• 武汉凯恩医院作为 EUDA 在中国中部的临床和长寿旗舰，计划的低温生物存储和临床能力设计支持约 200,000 个患者细胞单位，整合住院、门诊和长期健康管理服务。</p>
<p>• 通过合作诊所网络提供全国临床接入层，支持本地提取和下游临床交付。</p>
<p><strong>武汉凯恩医院</strong></p>
<p>武汉凯恩医院是一家以长寿为重点的优质健康管理医院，定位为五星级综合抗衰老和预防医疗中心，汇集再生医学、非药物慢性病管理、激素和代谢平衡、免疫支持、早期预警诊断和个性化长期健康规划于一体。它被建立为整合先进诊断和早期疾病风险检测、再生和基于细胞的医疗技术、个性化健康管理程序以及跨学科临床团队的旗舰模型，涵盖再生医学、内分泌学、心血管健康、免疫健康和长寿科学。在 EUDA 的平台下，武汉凯恩医院将同时作为临床交付地点和中部地区干细胞处理、存储和临床转化的中心节点。</p>
<p><strong>分布式临床接入和集中处理网络</strong></p>
<p>为了实现全国范围的接入，EUDA 正在与两家战略基础设施合作伙伴合作。广东万海细胞生物技术有限公司运营着一个全国性的网络，包括符合 cGMP 标准的实验室、区域细胞制备中心和附属临床制备及治疗场所，以及覆盖中国 20 多个省市的约 200 个制备和治疗诊所的广泛网络，提供合格患者进行提取、临床制备和后处理协调的物理接入点。顺丰冷链物流有限公司专注于受监管的、温控的城际运输细胞和生物材料，支持在受控冷链条件下在提取诊所、处理设施和治疗中心之间安全运输患者样本。</p>
<p>通过这一综合结构，患者可以在全国合作伙伴网络内的参与诊所进行干细胞提取，提取的细胞材料随后在冷链协议下运输到深圳英诺免疫或武汉凯恩医院进行处理和低温存储。当临床适宜时，准备好的细胞产品会被运输回指定诊所供患者使用，物流协调和监护链追踪通过专用的生物医学冷链系统进行管理。这一架构使 EUDA 能够提供地理分布的接入，同时保持集中质量控制，支持可扩展性，同时保持处理一致性。</p>
<p><strong>EUDA 首席执行官阿尔弗雷德·林（Mr Alfred Lim）评论道：</strong></p>
<p>“这个平台改变了再生医学在中国的获取和交付方式。我们不是在孤立的诊所或实验室，而是在构建一个协调的国家系统，将提取、低温存储、物流和临床交付连接成一个综合生态系统。以深圳英诺免疫和武汉凯恩医院为我们的支柱，结合我们的全国诊所和物流合作伙伴的扩展，我们相信我们正在为该地区创造一个全面且可扩展的再生医学接入基础设施。”</p>
<p><strong>关于 EUDA Health Holdings Limited</strong></p>
<p>EUDA Health Holdings Limited（纳斯达克代码：EUDA）是一家总部位于新加坡的领先非侵入性医疗服务提供商，专注于新加坡、马来西亚和中国。该公司旨在成为非侵入性和预防性医疗领域的市场领导者，战略重点放在快速增长的长寿产业上。我们的使命是满足该地区超过 18 亿人不断变化的医疗需求，该地区正经历显著的人口结构变化，超过 30% 的人口迅速老龄化。通过提供创新、可及且有科学依据的健康解决方案，EUDA 致力于引领区域医疗从被动的医疗治疗转向主动的、以长寿为中心的护理。EUDA 还经营一家总部位于新加坡的物业管理业务。</p>
<p><strong>前瞻性声明</strong></p>
<p>本文件可能包含关于风险和不确定性的前瞻性声明。这些声明通常使用前瞻性词汇，例如 “估计”、“预测”、“期望”、“设想”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词的变体或类似表达（或这些词或表达的否定版本）。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了 EUDA 的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有重大差异。您不应过度依赖仅适用于本文件发布之日的前瞻性声明。除法律要求外，公司不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>联系方式</strong></p>
<p>Christensen Advisory</p>
<p>Linda Bergkamp</p>
<p>电话：+1-480-614-3004</p>
<p>电子邮件：linda.bergkamp@christensencomms.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

EUDA

<p>EUDA Health Holdings Limited 在中国推出了一项全国性的干细胞提取、冷冻储存和临床交付平台，合作伙伴包括深圳创新免疫和武汉凯恩医院。该平台旨在通过集中处理系统和分散访问来增强再生医学的可及性。主要特点包括在中国南方具备 50,000 个患者细胞单位的低温储存能力，在中国中部则为 200,000 个，并由提取和治疗的诊所网络支持。首席执行官阿尔弗雷德·林强调了在该地区建立全面再生医学基础设施的重要性</p>

<p><strong>SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) --</strong> EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. This platform marks a major step in EUDA’s continued advancement of its stem cell strategy, further extending its capabilities across cell extraction, processing, cryogenic storage, logistics and clinical application.</p>
<div class="lb-trans"><p><strong>新加坡，2025 年 12 月 30 日（GLOBE NEWSWIRE）--</strong> EUDA Health Holdings Limited（纳斯达克：EUDA）“EUDA” 或 “公司”，是一家总部位于新加坡的非侵入性医疗保健提供商，专注于新加坡、马来西亚和中国，今天宣布在中国推出其全国性的干细胞提取、低温存储和临床交付平台。公司已与深圳英诺免疫有限公司和武汉凯恩医院建立合作关系，继续扩展其全国临床和物流网络。该平台标志着 EUDA 在干细胞战略持续推进中的重要一步，进一步扩展了其在细胞提取、处理、低温存储、物流和临床应用方面的能力。</p>
</div><p><strong>Core Platform Design Principles</strong></p>
<div class="lb-trans"><p><strong>核心平台设计原则</strong></p>
</div><p>EUDA’s platform is designed around three core principles: centralized processing with decentralized access to ensure quality and compliance without limiting geographic reach, long-term cell preservation to enable patients to store biological material earlier in life for potential future clinical use, and integration with longevity medicine so that cell services are embedded within broader preventive, regenerative and personalized health programs.</p>
<div class="lb-trans"><p>EUDA 的平台围绕三个核心原则设计：集中处理与分散访问相结合，以确保质量和合规性而不限制地理覆盖范围；长期细胞保存，使患者能够在生命早期存储生物材料以备未来临床使用；与长寿医学的整合，使细胞服务嵌入更广泛的预防、再生和个性化健康计划中。</p>
</div><p><strong>National Stem Cell Extraction and Cryostorage Infrastructure</strong></p>
<div class="lb-trans"><p><strong>国家干细胞提取和低温存储基础设施</strong></p>
</div><p>EUDA’s platform is designed as a closed-loop, compliant operating system that enables patients to access stem cell services across a wide geographic footprint while maintaining centralized processing standards.</p>
<div class="lb-trans"><p>EUDA 的平台被设计为一个闭环、合规的操作系统，使患者能够在广泛的地理范围内访问干细胞服务，同时保持集中处理标准。</p>
</div><p>Key elements include:</p>
<div class="lb-trans"><p>关键要素包括：</p>
</div><p>• Shenzhen Inno Immune Co., Ltd. as EUDA’s primary cell processing and cryogenic storage hub in Southern China, with an initial designed cryogenic storage capacity of approximately 50,000 patient cell units under controlled conditions.</p>
<div class="lb-trans"><p>• 深圳英诺免疫有限公司作为 EUDA 在中国南方的主要细胞处理和低温存储中心，初步设计的低温存储能力约为 50,000 个患者细胞单位，处于受控条件下。</p>
</div><p>• Wuhan Kaien Hospital as EUDA’s Central China clinical and longevity flagship, with a planned cryogenic biostorage and clinical capacity designed to support up to approximately 200,000 patient cell units, integrated with inpatient, outpatient and long-term health management services.</p>
<div class="lb-trans"><p>• 武汉凯恩医院作为 EUDA 在中国中部的临床和长寿旗舰，计划的低温生物存储和临床能力设计支持约 200,000 个患者细胞单位，整合住院、门诊和长期健康管理服务。</p>
</div><p>• A nationwide clinical access layer via partner clinic networks enabling local extraction and downstream clinical delivery.</p>
<div class="lb-trans"><p>• 通过合作诊所网络提供全国临床接入层，支持本地提取和下游临床交付。</p>
</div><p><strong>Wuhan Kaien Hospital</strong></p>
<div class="lb-trans"><p><strong>武汉凯恩医院</strong></p>
</div><p>Wuhan Kaien Hospital is a premium longevity-focused health management hospital positioned as a five-star, integrated anti-aging and preventive healthcare center that brings together regenerative medicine, non-drug chronic disease management, hormone and metabolic balance, immune support, early-warning diagnostics and personalized long-term health planning within one institutional setting. It was established as a flagship model for integrating advanced diagnostics and early disease risk detection, regenerative and cell-based medical technologies, personalized health management programs and multidisciplinary clinical teams spanning regenerative medicine, endocrinology, cardiovascular health, immune health and longevity science. Under EUDA’s platform, Wuhan Kaien Hospital will serve both as a clinical delivery site and as a central node for stem cell processing, storage and clinical translation in Central China.</p>
<div class="lb-trans"><p>武汉凯恩医院是一家以长寿为重点的优质健康管理医院，定位为五星级综合抗衰老和预防医疗中心，汇集再生医学、非药物慢性病管理、激素和代谢平衡、免疫支持、早期预警诊断和个性化长期健康规划于一体。它被建立为整合先进诊断和早期疾病风险检测、再生和基于细胞的医疗技术、个性化健康管理程序以及跨学科临床团队的旗舰模型，涵盖再生医学、内分泌学、心血管健康、免疫健康和长寿科学。在 EUDA 的平台下，武汉凯恩医院将同时作为临床交付地点和中部地区干细胞处理、存储和临床转化的中心节点。</p>
</div><p><strong>Distributed Clinical Access and Centralized Processing Network</strong></p>
<div class="lb-trans"><p><strong>分布式临床接入和集中处理网络</strong></p>
</div><p>To enable nationwide access, EUDA is working with two strategic infrastructure partners. Guangdong Wanhai Cell Biotechnology Co., Ltd. operates a nationwide footprint comprising cGMP-standardized laboratories, regional cell preparation centers and affiliated clinical preparation and treatment sites, and an extensive network of approximately 200 preparation and treatment clinics across more than 20 provinces and cities in China, providing physical access points where eligible patients can undergo extraction, clinical preparation and post-processing coordination. Shunfeng Cold Chain Logistics Co., Ltd. specializes in regulated, temperature-controlled intercity transport of cellular and biological materials and supports the secure movement of patient samples between extraction clinics, processing facilities and treatment centers under controlled cold-chain conditions.</p>
<div class="lb-trans"><p>为了实现全国范围的接入，EUDA 正在与两家战略基础设施合作伙伴合作。广东万海细胞生物技术有限公司运营着一个全国性的网络，包括符合 cGMP 标准的实验室、区域细胞制备中心和附属临床制备及治疗场所，以及覆盖中国 20 多个省市的约 200 个制备和治疗诊所的广泛网络，提供合格患者进行提取、临床制备和后处理协调的物理接入点。顺丰冷链物流有限公司专注于受监管的、温控的城际运输细胞和生物材料，支持在受控冷链条件下在提取诊所、处理设施和治疗中心之间安全运输患者样本。</p>
</div><p>Through this integrated structure, patients may undergo stem cell extraction at participating clinics within the national partner network, after which extracted cellular material is transported under cold-chain protocols to Shenzhen Inno Immune or Wuhan Kaien Hospital for processing and cryogenic storage. When clinically appropriate, prepared cell products are transported back to designated clinics for patient administration, with logistics coordination and chain-of-custody tracking managed through dedicated biomedical cold-chain systems. This architecture allows EUDA to offer geographically distributed access with centralized quality control, supporting scalability while maintaining processing consistency.</p>
<div class="lb-trans"><p>通过这一综合结构，患者可以在全国合作伙伴网络内的参与诊所进行干细胞提取，提取的细胞材料随后在冷链协议下运输到深圳英诺免疫或武汉凯恩医院进行处理和低温存储。当临床适宜时，准备好的细胞产品会被运输回指定诊所供患者使用，物流协调和监护链追踪通过专用的生物医学冷链系统进行管理。这一架构使 EUDA 能够提供地理分布的接入，同时保持集中质量控制，支持可扩展性，同时保持处理一致性。</p>
</div><p><strong>Mr Alfred Lim, CEO of EUDA, commented:</strong></p>
<div class="lb-trans"><p><strong>EUDA 首席执行官阿尔弗雷德·林（Mr Alfred Lim）评论道：</strong></p>
</div><p>“This platform transforms how regenerative medicine is accessed and delivered in China. Instead of isolated clinics or laboratories, we are building a coordinated national system connecting extraction, cryogenic storage, logistics and clinical delivery into one integrated ecosystem. With Shenzhen Inno Immune and Wuhan Kaien Hospital as our anchors, and our national clinic and logistics partners extending reach, we believe we are creating a comprehensive and scalable infrastructure for regenerative medicine access in the region.”</p>
<div class="lb-trans"><p>“这个平台改变了再生医学在中国的获取和交付方式。我们不是在孤立的诊所或实验室，而是在构建一个协调的国家系统，将提取、低温存储、物流和临床交付连接成一个综合生态系统。以深圳英诺免疫和武汉凯恩医院为我们的支柱，结合我们的全国诊所和物流合作伙伴的扩展，我们相信我们正在为该地区创造一个全面且可扩展的再生医学接入基础设施。”</p>
</div><p><strong>About EUDA Health Holdings Limited</strong></p>
<div class="lb-trans"><p><strong>关于 EUDA Health Holdings Limited</strong></p>
</div><p>EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.</p>
<div class="lb-trans"><p>EUDA Health Holdings Limited（纳斯达克代码：EUDA）是一家总部位于新加坡的领先非侵入性医疗服务提供商，专注于新加坡、马来西亚和中国。该公司旨在成为非侵入性和预防性医疗领域的市场领导者，战略重点放在快速增长的长寿产业上。我们的使命是满足该地区超过 18 亿人不断变化的医疗需求，该地区正经历显著的人口结构变化，超过 30% 的人口迅速老龄化。通过提供创新、可及且有科学依据的健康解决方案，EUDA 致力于引领区域医疗从被动的医疗治疗转向主动的、以长寿为中心的护理。EUDA 还经营一家总部位于新加坡的物业管理业务。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本文件可能包含关于风险和不确定性的前瞻性声明。这些声明通常使用前瞻性词汇，例如 “估计”、“预测”、“期望”、“设想”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词的变体或类似表达（或这些词或表达的否定版本）。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了 EUDA 的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有重大差异。您不应过度依赖仅适用于本文件发布之日的前瞻性声明。除法律要求外，公司不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Contact</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Christensen Advisory</p>
<div class="lb-trans"><p>Christensen Advisory</p>
</div><p>Linda Bergkamp</p>
<div class="lb-trans"><p>Linda Bergkamp</p>
</div><p>Phone: +1-480-614-3004</p>
<div class="lb-trans"><p>电话：+1-480-614-3004</p>
</div><p>E-mail: linda.bergkamp@christensencomms.com</p>
<div class="lb-trans"><p>电子邮件：linda.bergkamp@christensencomms.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODE3MiM3MzM5NjQ1IzUwMDEyNDQzOQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital | EUDA Stock News

Euda Health 在中国与深圳 Inno Immune 和武汉凯恩医院合作推出全国性的干细胞提取、冷冻储存和临床交付平台 | Euda Health 股票新闻